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Abstract: Elevated blood pressure (BP) is a major cause of death, yet hypertension commonly goes
undetected. Owing to its nature, it is typically asymptomatic until later in its progression when the
vessel or organ structure has already been compromised. Therefore, noninvasive and continuous BP
measurement methods are needed to ensure appropriate diagnosis and early management before
hypertension leads to irreversible complications. Photoplethysmography (PPG) is a noninvasive
technology with waveform morphologies similar to that of arterial BP waveforms, therefore attracting
interest regarding its usability in BP estimation. In recent years, wearable devices incorporating
PPG sensors have been proposed to improve the early diagnosis and management of hypertension.
Additionally, the need for improved accuracy and convenience has led to the development of devices
that incorporate multiple different biosignals with PPG. Through the addition of modalities such
as an electrocardiogram, a final measure of the pulse wave velocity is derived, which has been
proved to be inversely correlated to BP and to yield accurate estimations. This paper reviews and
summarizes recent studies within the period 2010–2019 that combined PPG with other biosignals
and offers perspectives on the strengths and weaknesses of current developments to guide future
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advancements in BP measurement. Our literature review reveals promising measurement accuracies
and we comment on the effective combinations of modalities and success of this technology.
Keywords: photoplethysmogram; PPG signal; pulse oximetry; hypertension assessment; hypertension
diagnosis; blood pressure measurement; wearable technology; wearable devices; digital health;
digital medicine; pulse arrival time; biomedical engineering
1. Introduction
Hypertension, or high blood pressure (BP), is a dangerous cardiac condition that accelerates end
organ damage if not properly managed [1]. As this condition does not present noticeable symptoms
early in its course, it is often not revealed unless regular BP monitoring is performed by health
professionals or through self-management. Therefore, BP monitoring is a vital component of the
diagnosis, management, and treatment of hypertension and early intervention is key for preventing
its negative outcomes [2]. Recent years have seen considerable interest in developing a technology
that is capable of accurately measuring continuous BP pressure both noninvasively and conveniently.
Conventional cuff-based BP measurement methods are unable to measure BP continuously and are
inconvenient and interruptive when measuring the ambulatory BP throughout the day and night.
In multimodal biosignal systems, the most common feature used to estimate BP is the pulse
wave velocity (PWV) [3]. The PWV is the speed at which a pressure wave travels down a segment of
fixed length d and it can be calculated as PWV = d/PTT, where PTT is the pulse transit time. Based
on the same idea, the pulse arrival time (PAT) is also tested and examined, and both PTT and PAT
have been found to be closely correlated with BP [4]. The PTT and PAT durations reflect the time
required for an arterial pressure wave to travel between a proximal and a distal site of an artery [5].
The difference being that the PAT includes an initial measurement at the heart, commonly measured
using electrocardiography (ECG), whereas the initial measurement site for PTT is located distally,
calculated by multi-site photoplethysmography (PPG) [6] or through utilization of other biosignals.
PAT and PTT measurements both require the accurate detection of pulse at the distal artery. This has
most commonly been measured using PPG as it has the ability to detect changes in blood pulsation
through monitoring the variation in light absorption from a photodetector placed near a light-emitting
diode [7]. Further details regarding the extraction of specific feature(s) from a single PPG signal and
how these features can be incorporated into BP estimations are discussed and examined in our previous
work [4,6,8–10]. This review focuses on evaluating various PPG-based multimodal biosignal systems
that have been investigated by researchers in an attempt to estimate BP and assess hypertension.
Combining Other Biosignals with PPG for BP Estimation
In recent literature, various photoplethysmography-based modalities have been introduced
to improve the assessment of hypertension, as shown in Figure 1. One of these modalities is the
simultaneous collection of electrocardiography (ECG) with PPG to estimate PAT [4]. The PAT is defined
as the time required for an arterial pressure wave to travel from the aorta to a peripheral location,
beginning from the electrical activation of the heart [11]. In practice, it is calculated based on the time
difference between the proximal QRS complex in the ECG waveform and the peak of the first derivative
of the PPG waveform measured at a distal artery in the same cardiac cycle [12]. It is important to note
that when PAT is measured from the Q-wave in ECG, it includes the pre-ejection period (PEP), which is
defined as the electromechanical delay and period of isovolumetric contraction in the left ventricle [13].
PEP has been shown to account for 12%–35% of PAT [14] and to significantly skew BP estimations
when not accounted for [13]. To derive the most accurate BP measurement from PAT, it is suggested
that the PEP be measured and removed, resulting in a measure of PTT [13].
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Figure 1. Determination of pulse arrival time and pulse transit time in various modalities that combine
photoplethysmography with biosignals for blood pressure estimation. ICG: impedance cardiography,
SCG: seismocardiography, ECG: electrocardiography, GCG: gyrocardiography, IPG: impedance
plethysmography, PPG: photoplethysmography, BCG: ballistocardiography, SBS: strain-based sensor,
PAT: pulse arrival time, PTT: pulse transit time.
To account for PEP, several studies have explored other technologies to derive a more accurate
representation of the opening of the aortic valve (AO) for use as a proximal timing indicator for PTT,
therefore removing the contribution of PEP. Wong et al. [13] successfully used impedance cardiography
(ICG) to calculate PEP based on the time difference between the ECG-Q-point and the ICG-B point
and removed it to yield a more accurate measurement of PTT. Kim et al. [15] investigated the use of
ballistocardiography (BCG) as a replacement for ECG as it does not include the PEP when measured
from the BCG-J-wave and can therefore potentially yield a more precise proximal timing reference for
PTT. Martin et al. [5] later confirmed the accuracy of this method by investigating a bathroom-scale-like
device that used BCG and foot PPG waveforms to successfully track BP better than PAT-BP [16].
Seismocardiography (SCG) measures the thoracic vibrations of the heart through an accelerometer
on the chest and the AO can be extracted from SCG waveforms, therefore avoiding the influence of
PEP [17]. However, this modality is sensitive to movement artifacts and interindividual variability
in morphology. Zhang et al. [11] proposed a wearable device and a supervised machine learning
algorithm to help correct for this limitation that proved to increase the BP measurement accuracy.
Similar to SCG, gyrocardiography (GCG) uses a gyroscope on the sternum to identify the AO by
locating the maximum on the GCG wave in each cardiac cycle. Yang et al. [18] extracted the AO
from SCG and GCG signals from the accelerometer and gyroscope of a smartphone, respectively,
and combined this with the PPG signals measured using a modified optical sensor in the audio output
to calculate PTT. The smartphone device resulted in superior PTT measurements compared to the
reference PTT calculated with standalone sensors.
Other less common biosignals have also been investigated over the years to determine their
suitability for incorporation into these modalities. For example, impedance plethysmography (IPG),
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which is defined as the electrical impedance of body tissues to an electric current, can be used to measure
the amount of blood in blood vessels. Ibrahim et al. [19] calculated PTT using the time difference
between the point of maximum negative inclination on the IPG waveform and the characteristic point
on the PPG waveform. Ibrahim et al.’s study [19], along with one conducted by Huynh et al. [20],
incorporated ICG sensors at the wrist as the proximal timing reference to a PPG sensor at the finger
to yield a measurement of PTT that was more conveniently detected and comfortable for the user
than the traditional ECG-PPG modality. The ICG-PPG modality produced correlation coefficients of
0.84 [19] and 0.88 [20] for SBP estimation, however very small sample sizes of n = 3 [19] and n = 15 [20]
indicates the need for further validation. Overall, these results suggest that incorporating ICG into
PTT based BP estimation techniques holds potential for yielding accurate results with a wearable and
user-friendly device.
This review aims to summarize recent technological advancements and offer perspectives on
recent literature concerning the combination of PPG and other biosignal modalities for continuous,
noninvasive BP measurement. In our analysis of scientific publications from January 2010 to January
2019, we highlight several factors that are important for future research, including global trends,
the comparison to a validated gold standard, and appropriate subject recruitment. We summarize the
overall accuracy reported in the included studies and a breakdown by the used modality combinations
to provide recommendations and direction for future research endeavors.
2. Methods
2.1. Literature Search
We used the PubMed database to search for literature that investigates a combination of PPG
technology and other biosignals for BP measurement. As we were interested in the most recent
technological advancements, we chose to include studies from the most recent decade; studies were
published between the dates 1 January 2010 and 1 January 2019. The search terms we used were a
combination of the Medical Subject Heading terms “blood pressure,” “blood pressure determination,”
“arterial pressure,” “hypertension,” “photoplethysmography,” and “pulse wave analysis,” as well as
the general terms “analysis,” “classification,” “blood pressure monitoring,” “pulse wave analysis,”
and “pulse transit time.” We chose to exclude “arterial stiffness” by including the search term “NOT
arterial stiffness,” as the inclusion of this term yielded many studies that investigated the impact of
vascular disease on biosignals but were not directly related to BP estimation. In total, the search yielded
1,098 results; 73 of which met our inclusion criteria and were included in the analysis. Papers were
included in our review if they could be accessed in English and used PPG signals with simultaneously
recorded but different biosignals to obtain BP estimations. We excluded review articles, animal
studies, and studies that did not use both PPG and a different modality to calculate BP (see Figure 2).
We recognize that a potential limitation of our review is the possibility of search engine bias. Only
articles that were tagged with these terms were included and therefore, qualifying articles may have
been missed in the search.
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Figure 2. Flowchart of the methodology used to include 73 out of 1,098 published studies from 2010–2019.
2.2. Statistical Analysis
As part of our analysis, we decided to present two of the most consistently reported measurements
of accuracy to summarize the outcomes in the field. The mean error and standard deviation were
extracted from studies that compared the estimated and reference BP for both SBP and DBP. Of the
73 included studies, 14 reported these values. Studies that did not include the BP mean error and
standard deviation data were excluded from this error analysis. The second value we collected was
Pearson’s correlation efficient (r) as it was reported in several studies. Values were included if the
r values were used to compare the estimated and reference BP for both SBP and DBP. We felt that
this was an important inclusion criterion as accurately measuring DBP using PPG-based technologies
remains challenging and is an area for improvement. Of the 73 studies that reported correlation
results, 22 met this criterion. Three studies [21–23] included in this analysis reported the coefficient
of determination (r2) instead of r. To include these studies, we used the square root (r) of this value.
On a few occasions, studies did not report an overall mean error or r and instead reported multiple
values of each population they tested. These studies separately analyzed male and female groups [21],
healthy participants and participants with heart disease [22], and participants whose BP was estimated
during static exercise and those whose BP was estimated with a cold pressor test [23]. In the first two,
to account for the multiple r values and include them in our results, we took the average between
the two study populations to produce a combined r. In the third, we used static exercise data on
the grounds that it was more applicable to the results of this review. In addition, several studies
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reported correlations between PTT/PAT and BP or mean arterial pressure (MAP) instead of SBP and
DBP. They were not included in this analysis in an attempt to standardize the extracted data.
3. Results
3.1. Global Distribution and Combinations of Biosignals Used in Literature
Our literature search returned 73 scientific publications that met our inclusion criteria, all of
which were included in our analysis (Table 1). To gain a better understanding of the trends and
geographical distribution of the included papers, we analyzed the data by year and country as well as
the modalities used to calculate BP. The distribution by continent indicated that Asia provided the
most significant contribution to the field with 42 publications, as shown in Figure 3. With Asia as the
front runner in terms of volume of research, we recommend that other countries continue or increase
their investigations in this field, given the substantial impact of hypertension on the health status
and quality of life of individuals worldwide. As the intention of this research is to create a validated
BP estimation device for use across various populations, the ideal device would be validated across
individuals of various ethnic backgrounds from around the world.
Table 1. Summary findings of the 73 papers included in this review. Studies that reported values for multiple
study populations have been averaged for simplicity as per our methods and represented in italic. Studies
that achieved mean difference and standard deviation for both SBP and DBP within the ANSI/AAMI/ISO
81060–2:2013 (mean difference of test versus reference BP measurements ≤ 5 mmHg with standard
deviation ≤ 8 mmHg for systolic and diastolic BP) [24] are represented in bold. M: males, F: females, BP:
blood pressure, NTN: normotensive, HTN: hypertensive, ABP: invasive arterial blood pressure, CBP:
cuff blood pressure, FABP: finger arterial blood pressure, PAT: Pulse arrival time, PTT: Pulse transit time,
ME: mean error, SD: standard deviation, SBP: systolic blood pressure, DBP: diastolic blood pressure,
N/R: not reported, ECG: electrocardiogram, SCG: seismocardiogram, BCG: ballistocardiogram, ICG:
impedance cardiogram, GCG: gyrocardiogram, IPG: impedance plethysmography, SBS: strain-based
sensor, PIR: PPG intensity ratio, HPSR: heart-power spectrum ratio. M1: modality 1 (PPG + ECG), M2:
modality 2 (PPG + BCG), M3: modality 3 (PPG + SCG), M4: modality 4 (PPG + IPG), M5: modality
5 (PPG + SBS), M6: modality 6 (PPG + ICG), M7: modality 7 (PPG + ECG + ICG), M8: modality 8
(PPG + ECG + BCG), M9: modality 9 (PPG + SCG + GCG), M10: modality 10 (PPG + ECG + SCG).
Publication # Subjects(M:F) BP Status Comorbidities
Gold
Standard
Modality
Category ME ± SD (mmHg)
Pearson’s
Coefficient (r)
Baek et al. (2010) [25] 15 (11:4) NTN Yes ABP, FABP M1 SBP = N/RDBP = N/R
SBP = 0.815
DBP = 0.779
Chua et al. (2010) [26] 18 (14:4) NTN No FABP M1 SBP = N/RDBP = N/R
SBP = 0.73
DBP = N/R
Proença et al. (2010) [12] 20 (14:6) NTN No FABP M7 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Wong et al. (2011) [13] 22 (14:8) NTN No ABP M7 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Mase et al. (2011) [27] 33 (19:14) NTN,HTN Yes CBP MI
SBP = N/R
DBP = N/R
SBP = 0.89
DBP = 0.78
Gesche et al. (2012) [28] 63 (36:27) NTN No CBP M1 SBP = N/RDBP = N/R
SBP = 0.83
DBP = N/R
Kato et al. (2012) [29] 1 (1:0) NTN No CBP M8 SBP = N/RDBP = N/R
SBP = 0.805
DBP = 0.633
Baek et al. (2012) [30] 5 (5:0) NTN No FABP M1 SBP = N/RDBP = N/R
SBP = 0.848
DBP = N/R
Kim et al. (2013) [31] 23 (17:6) HTN Yes ABP M1 SBP = N/RDBP = N/R
SBP = 0.81
DBP = 0.81
Spießhöfer et al. (2013) [32] 29 (27:2) N/R Yes CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Chen et al. (2013) [33] 5 (N/R) NTN No CBP M2 SBP = 9.0 ± 5.6DBP = 1.8 ± 1.3
SBP = N/R
DBP = N/R
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Table 1. Cont.
Publication # Subjects(M:F) BP Status Comorbidities
Gold
Standard
Modality
Category ME ± SD (mmHg)
Pearson’s
Coefficient (r)
Puke et al. (2013) [34] 4 (3:1) N/R N/R CBP M1 SBP = 6.91 ± 4.23DBP = N/R
SBP = N/R
DBP = N/R
Couceiro et al. (2013) [35] 43 (23:20) N/R Yes FABP M7 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Solà et al. (2013) [36] 15 (15:0) NTN No CBP M7 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Jeong & Finkelstein (2013) [37] 5 (2:3) NTN No CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Wang et al. (2014) [38] 6 (N/R) N/R N/R CBP M1 SBP = 0.04 ± 3.78DBP = −0.01 ± 4.34
SBP = N/R
DBP = N/R
Thomas et al. (2014) [39] 4 (N/R) N/R N/R CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Ma, HT (2014) [40] 30 (N/R) NTN No CBP M1 SBP = N/RDBP = N/R
SBP R2 = 0.96
DBP R2 = 0.71
Zhang et al. (2014) [41] 2 (N/R) N/R Yes ABP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Vlahandonis et al. (2014) [42] 25 (12:18) NTN Yes CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Younessi heravi et al. (2014) [21] 25 (15:10) N/R N/R CBP M1 SBP = 6.73 ± 2.68DBP = 8.13 ± 3.18
SBP = 0.89
DBP = 0.82
Gomez Garcia et al. (2014) [43] 30 (20:10) NTN,HTN Yes CBP M1
SBP = −0.2 ± 2.4
DBP = N/R
SBP = 0.88
DBP = 0.58
Wibmer et al. (2014) [44] 20 (14:6) NTN,HTN Yes CBP M1
SBP = N/R
DBP = N/R
SBP R2 = 0.92
DBP R2 = 0.46
Zheng et al. (2014) [45] 10 (N/R) NTN No CBP M1 SBP = 2.8 ± 8.2DBP = N/R
SBP = N/R
DBP = N/R
Liu et al. (2014) [46] 46 (34:7) NTN,HTN Yes CBP, FABP M1
SBP = N/R
DBP = N/R
SBP = N/R
DBP = N/R
Liu et al. (2015) [47] 10 (6:4) NTN No CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Tang et al. (2015) [48] 9 (9:0) NTN No CBP, FABP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Ding & Zhang (2015) [16] 5 (N/R) NTN No FABP M1 + PIR SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Tamura et al. (2015) [49] 9 (9:0) NTN No FABP M1 0.7 ± 3.65(Unclear if SBP or DBP)
SBP = N/R
DBP = N/R
Kim et al. (2015) [15] 15 (10:5) NTN No PAT M2 SBP = N/RDBP = N/R
SBP = 0.81
DBP = 0.83
Wibmer et al. (2015) [50] 18 (11:7) NTN,HTN Yes CBP M1
SBP = N/R
DBP = N/R
SBP = 0.93
DBP = N/R
Ding et al. (2016) [51] 27 (14:13) NTN No FABP M1 + PIR SBP = −0.037 ± 5.21DBP = −0.08 ± 4.06
SBP = 0.91
DBP = 0.88
Thomas et al. (2016) [52] 11 (N/R) NTN No CBP M1 SBP = N/RDBP = N/R
SBP = 0.72
DBP = 0.70
Sun et al. (2016) [53] 19 (14:5) N/R No FABP M1 SBP = 0.43 ± 13.52DBP = N/R
SBP = 0.93
DBP = N/R
Ding et al. (2016) [22] 85 (37:48) NTN, HTN Yes CBP M1 SBP = −1.55 ± 13.79DBP = 0.07 ± 8.49
SBP = N/R
DBP = N/R
Martin et al. (2016) [5] 22 (19:3) NTN No FABP M2 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Dai et al. (2016) [54] 7 (N/R) NTN No FABP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Zhang et al. (2016) [11] 2 (N/R) NTN N/R CBP M8 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Shahrbabaki et al. (2016) [55] 10 (N/R) N/R N/R CBP M1 SBP = N/RDBP = N/R
SBP R2 = 0.59
DBP R2 = 0.42
Gholamhosseini et al. (2016) [56] 13 (N/R) N/R N/R CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Schoot et al. (2016) [57] 37 (18:19) NTN,HTN Yes CBP M1
SBP = N/R
DBP = N/R
SBP = N/R
DBP = N/R
Jain et al. (2016) [58] 72 (N/R) N/R N/R CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Liu et al. (2016) [7] 20 (N/R) NTN,HTN Yes FABP M1
SBP = N/R
DBP = N/R
SBP R2 = 0.95
DBP = N/R
Kachuee et al. (2017) [59] 1000 (N/R) N/R N/R ABP M1 SBP = −0.06 ± 9.88DBP = 0.36 ± 5.7
SBP = 0.54
DBP = 0.57
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Table 1. Cont.
Publication # Subjects(M:F) BP Status Comorbidities
Gold
Standard
Modality
Category ME ± SD (mmHg)
Pearson’s
Coefficient (r)
Tang et al. (2017) [60] 12 (11:1) NTN,HTN No ABP M1
SBP = 0.2 ± 5.8
DBP = 0.4 ± 5.7
SBP = 0.92
DBP = 0.64
Seeberg et al. (2017) [61] 18 (15:3) N/R Yes CBP, FABP M7 SBP = N/RDBP = N/R
SBP = 0.69
DBP = 0.38
Janjua et al. (2017) [62] 11 (9:2) NTN No CBP M8 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Liu et al. (2017) [63] 20 (N/R) NTN No CBP M7 SBP = N/RDBP = N/R
SBP = 0.7
DBP = N/R
Chen et al. (2017) [64] 10 (5:5) NTN No FABP M1 SBP = −0.91 ± 3.84DBP = −0.36 ± 3.36
SBP = N/R
DBP = N/R
Ahmaniemi et al. (2017) [65] 30 (N/R) NTN No CBP M1 SBP = N/RDBP = N/R
SBP = 0.42
DBP = 0.06
Zhang et al. (2017) [66] 10 (7:3) N/R N/R CBP M1 SBP = 1.63 ± 4.4DBP = N/R
SBP = N/R
DBP = N/R
Lin et al. (2017) [67] 22 (N/R) NTN No CBP M1 + PIR SBP = 3.22 ± 8.02DBP = 3.13 ± 4.82
SBP = 0.93
DBP = 0.95
Bhattacharya et al. (2017) [68] 6 (N/R) N/R N/R CBP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Ding et al. (2017) [69] 33 (N/R) NTN,HTN Yes FABP M1 + PIR
SBP = 1.17 ± 5.72
DBP = 0.46 ± 5.49
SBP = N/R
DBP = N/R
Pflugradt et al. (2017) [70] N/R (N/R) N/R N/R ABP M1 SBP = 0.015 ± 4.41DBP = N/R
SBP = N/R
DBP = N/R
Ding et al. (2017) [71] 6 (N/R) N/R N/R ABP M1 + PIR SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Xu et al. (2017) [72] 10 (8:2) N/R N/R CBP M1 SBP = 4.5 ± 6.13DBP = 3.4 ± 3.37
SBP = N/R
DBP = N/R
Ibrahim et al. (2017) [19] 3 (N/R) N/R N/R PTT, FABP M6 SBP = N/RDBP = N/R
SBP = 0.84
DBP = N/R
Lo et al. (2017) [73] 25 (N/R) N/R N/R ABP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Yang & Tavassolian (2018) [17] 10 (10:0) NTN No CBP M3 SBP = N/RDBP = N/R
SBP = 0.58
DBP = 0.57
Rajala et al. (2018) [74] 30 (19:11) NTN No CBP MI SBP = N/RDBP = N/R
SBP = 0.37
DBP = N/R
Wang et al. (2018) [75] 59 (N/R) N/R N/R CBP M5 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Lin et al. (2018) [76] 22 (N/R) NTN No FABP M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Kim et al. (2018) [77] N/R (N/R) N/R N/R PAT M1 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Sharifi et al. (2018) [78] 1000 (N/R) N/R N/R ABP M1 + PIR SBP = −0.29 ± 9.1DBP = −0.1 ± 8.62
SBP = N/R
DBP = N/R
Ahmaniemi et al. (2018) [79] 10 (9:1) NTN No FABP MI SBP = 9.8DBP = N/R
SBP = 0.75
DBP = N/R
Liang et al. (2018) [80] 121 (N/R) NTN,HTN Yes ABP M1
SBP = N/R
DBP = N/R
SBP = N/R
DBP = N/R
Yang et al. (2018) [18] 10 (N/R) NTN No PTT M9 SBP = N/RDBP = N/R
SBP = N/R
DBP = N/R
Xu et al. (2018) [81] 41 (21:21) NTN No CBP M1 SBP = N/RDBP = N/R
SBP = 0.817
DBP = 0.757
Chen et al. (2018) [82] 60 (40:20) NTN,HTN Yes CBP
M1 + PIR,
HPSR
SBP = 0.61 ± 9.36
DBP = 0.68 ± 6.67
SBP = 0.93
DBP = 0.89
Lee et al. (2018) [23] 11 (11:0) NTN No FABP M10 SBP = N/RDBP = N/R
SBP = 0.915
DBP = 0.854
Feng et al. (2018) [83] 28 (15:13) N/R Yes ABP M1 SBP = −0.98 ± 6.0DBP = 0.02 ± 4.98
SBP = N/R
DBP = N/R
Huynh et al. (2018) [20] 15 (10:5) NTN No CBP M4 SBP = N/RDBP = N/R
SBP = 0.88
DBP = 0.88
Over the period January 2010–January 2019, there was an overall positive trend in the number of
papers published each year that used multiple biosignals for PPG-BP measurement. In more recent
years, we see a rising trend in the emergence of new combinations of various biosignals (Figure 4).
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Figure 3. Global distribution of scientific articles that discussed PPG signals in combination with other
biosignals to assess blood pressure from 2010–2019. The top five contributing countries are China (22),
USA (14), Germany (8), Korea (6), and Japan (5), which collectively produced 67% of the publications.
The number of publications per country is indicated by the intensity of the color, with darker colors
representing a higher number of articles than lighter colors.
Figure 4. Number of publications per year and associated biosignal modalities that were combined
with PPG from 2010–2019. M1-10: Various modality combinations of PPG: photoplethysmography
with; ECG: electrocardiogram, SCG: seismocardiogram, BCG: ballistocardiogram, ICG: impedance
cardiogram, GCG: gyrocardiogram, IPG: impedance plethysmography, and SBS: strain-based sensor.
It can be observed that ECG is the dominant modality across all years.
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Of the 73 included studies, 22 reported the correlation (r) between estimated and reference BP for
both SBP and DBP [15,17,20,21,23,25,27,29,31,40,43,44,51,52,55,59–61,65,67,81,82]. Further, 15 studies
reported the measurement variance in estimated versus reference BP for both SBP and DBP through
mean error and standard deviation [21,22,33,34,38,51,59,60,64,67,69,72,78,82,83]. Various different
biosignal combinations of ECG, BCG, SCG, ICG, IPG, and SBS were combined with PPG for BP
estimation. Several studies investigated the possibility of including additional features, such PPG
intensity ratio (PIR) and heart-power spectrum ratio (HRPS), into regression models in an attempt to
improve accuracy, however their results were comparable to those of other studies.
To determine the relative accuracy of the proposed technologies, we included the reported mean
error and standard deviation (Table 1) as outlined in our methods. Overall, the studies that reported
these values came exclusively from M1 (PPG + ECG), and the average mean error of studies that
reported values for both SBP and DBP was 1.7 mmHg (SBP) and 1.3 mmHg (DBP).
Figure 5 shows the reported r from studies that included these values for both SBP and DBP.
The validation of the correlation is compared to the sample size (n): the stronger the correlation and
the larger the sample size, the more accurate the reported r may be. The average r for SBP and DBP,
respectively, is 0.84 and 0.70 for M1, 0.81 and 0.81 for M2, 0.58 and 0.57 for M3, 0.88 and 0.88 for M4, 0.69
and 0.38 for M7, 0.81 and 0.63 for M8, and 0.92 and 0.85 for M10. Of the 55 studies in M1, the average
r was calculated from the 15 studies that met this criterion, with the highest reported r for SBP and
DBP being 0.98 and 0.84, respectively, and the lowest being 0.42 and 0.06, respectively. As only one
study from each of M2, M3, M4, M7, M8, and M10 was included in this analysis of reported correlation,
the average r reflects these single respective studies. Several studies did not report the correlation
coefficients of their data and therefore, M5, M6, and M9 are not included in this analysis. It should
be noted that this representation of accuracy does not reflect the entire dataset of included studies as
measurements of accuracy were reported in different ways.
Figure 5. Relationship between reported correlation coefficients (r) of estimated vs. reference SBP
and DBP and sample size (n) across all biosignal modalities. M1: modality 1 (PPG + ECG), M2:
modality 2 (PPG + BCG), M3: modality 3 (PPG + SCG), M4: modality 4 (PPG + IPG), M7: modality
7 (PPG + ECG + ICG), M8: modality 8 (PPG + ECG + BCG), M10: modality 10 (PPG + ECG + SCG).
Study strength (represented by the dashed line): the positive relationship between r and n in each study.
If a study is able to achieve a high correlation over a large group of participants, it is less likely to be due
to chance and it can be concluded that the correlation values are more likely to be true and validated
over a variety of individuals. Therefore, data points are plotted by the strength of the correlation to the
sample size and therefore, data points in the top right corner are considered to be the strongest, whereas
those in the bottom left corner are considered to be the weakest. M1 is the modality with the most data
points and the strongest r. M1 is also the only category to include studies with sample sizes over 30,
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making the correlations stronger than those of studies with small sample sizes. Across most modalities,
SBP estimations have consistently higher correlations with real SBP than DBP estimations do with real
DBP [17,21,23,25,27,40,43,44,51,52,55,60,61,65,81,82]. Three studies from M2 [15], M1 [59], and M1 [67]
showed the opposite trend and two studies from M1 [31] and M4 [20] reported the same r for both SBP
and DBP. Note that M5 (modality 5: PPG + SBS), M6 (modality 6: PPG + ICG), and M9 (modality 9:
PPG + SCG + GCG) are not included in the above figure as these studies did not report correlation
values for SBP and DBP.
3.2. Sample Size and Patient Demographics
The 17 studies with large sample sizes (n > 100) pulled subject data from databases; most commonly,
they used the Medical Information Mart for Intensive Care (MIMIC) database. However, pulling data
from this database is associated with a few notable limitations. As mentioned by Liang et al. [80], signals
are assumed to be synchronized when collected simultaneously; however, this is not always the case.
As some features are synchronicity-dependent, this can lead to unaccounted errors. In addition, patient
data in this database are recorded from the ICU, which means that medications and comorbidities are
most likely present; however, they are not included in the extracted data and are therefore not reported.
Figure 6a–c shows a summary of the results in terms of comorbidities, BP, and gender.
Figure 6. Patient demographics regarding health status, BP status, and gender reported in studies
published from 2010–2019. (a) With comorbidity: reported diagnosed diseases in their participants.
Without comorbidity: tested only healthy participants. No comorbidity reported: it was not reported if
the subjects were normotensive vs. hypertensive and if the subjects had comorbidities or not. (b) HTN
and NTN: documented number of subjects with and without hypertension. NTN only: only included
healthy subjects. No HTN Status: did not disclose the BP status of their subjects. (c) Males only: tested
only males. Female and male: tested both females and males. No gender reported: did not report the
gender of their subjects.
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In Figure 6a, the green bars show that there is a trend to not properly report the comorbidities of
participants. In Figure 6b, the purple bars and yellow bars show that there is a declining trend with
including hypertensive subjects in the studies. In Figure 6c, the dark pink bars show an increasing
trend in not reporting the gender in their studies.
The most commonly reported comorbidities were hypertension, type 2 diabetes mellitus,
cardiovascular disease, congestive heart failure, pulmonary disease, atrial fibrillation, and obstructive
sleep apnea, all of which affect the cardiovascular system. Only 12 papers included participants
with hypertension and 25 did not disclose BP status. Another interesting observation concerns the
reporting of medications that coincide with subjects’ comorbidities. Out of the 19 studies that reported
comorbidities, only five reported corresponding medications taken by their subject population. Some
of the most commonly reported medications included beta blockers, calcium channel blockers, ACE
inhibitors, diuretics, and nitrates. Three of the included studies [35,71,84] included intentionally
administered medications as part of the experimental procedure. The majority of studies (i.e., 37)
reported subjects of both genders. Surprisingly, 29 papers did not report the gender of their participants
and seven studies included only men. No studies included pregnant women as participants.
3.3. Appropriate Gold Standard
Using an established gold standard to validate novel methods is an important factor affecting
the quality of the evidence produced by these studies. Invasive arterial blood pressure (ABP)
measurement through an arterial catheter and cuff-based arterial blood pressure (CBP) measurement
with a sphygmomanometer are known to be the gold standards for BP measurement [85]. After analysis,
we found that 11 studies were able to compare their BP estimations to ABP and 42 studies used CBP as
their reference. As ABP is usually not feasible, owing to its invasive nature, many studies that used
this measure extracted data from the MIMIC database or used patients who were under anesthesia in
surgical conditions. Our analysis found that 17 studies used devices such as the Finometer, which uses
PPG technology and the volume-clamp method to measure the finger arterial blood pressure (FABP),
to obtain their reference BP measurements. The comparison to a non-validated device is noted as a
limitation in the majority of these papers. Three studies did not involve a comparison with any of
the above devices and instead directly compared their results to a PTT calculation from a previously
investigated device.
4. Discussion
Our review provides readers and researchers with a relative summary of the technological
advancements in the field of PPG and biosignals for BP measurement over recent years. Through our
analysis, we discovered several noteworthy points related to the accuracy of the proposed methods,
reporting of patient demographics, and testing conditions.
4.1. Accuracy of Proposed Methods
Most studies used ECG, which has been validated, owing to its consistently high correlations and
low error. Of the studies included in our analysis of error, only seven met the criteria for validation
based on the clinical standards set by the Association for the Advancement of Medical Instrumentation
(AAMI), as seen in Table 1. In an attempt to improve accuracy, some researchers have incorporated
HR into their calculations. For example, Wang et al. [38] showed a significant correlation between
HR and BP and demonstrated that the addition of both HR and previous BP measurements to the
PTT-BP estimation significantly improved the error (p < 0.05). Other measurements such as PIR have
been incorporated into the PTT-BP estimation [16,51,67,69,71,78,82] as it reflects the low-frequency
component of arterial diameter changes, which are not normally picked up by conventional PTT
measurements. Here, PIR is measured as the ratio of minimum to maximum amplitudes of a
PPG waveform in one cardiac cycle. Ding et al. [69] proved that the addition of PIR improved BP
estimation, decreased error, and maintained accuracy over extended (24 h) calibration periods; however,
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other studies incorporating PIR struggled to obtain acceptable SD values. Recently, the heart-rate power
spectrum ratio (HPSR), a new parameter, has been added to PTT-PIR estimation to more accurately
identify the increase in sympathetic activity in hypertensive patients [82]. Alterations in sympathetic
tone, adrenergic overflow, and parasympathetic tone contribute to changes in the factors that regulate
BP and decrease the accuracy of PPT-BP estimation in this population. Chen et al. [82] concluded that
the addition of HPSR resulted in superior estimation error, especially in the hypertensive population;
however, the standard deviation was still higher than the acceptable standard set by the AAMI.
It can be concluded that more work is needed surrounding decreasing error and standard deviation
values before many of these proposed technologies meet the appropriate validation standards to be
used clinically.
The use of devices with SCG, BCG, and ICG has not been widely validated or accepted, largely
owing to their susceptibility to error caused by motion artifacts and device complexity with an extra
sensor [33,61]. Interestingly, one of the highest correlations (0.92 and 0.85 for SBP and DBP, respectively)
was reported by a study [23] that investigated a combination of PPG, ECG, and SCG during static
exercise; however, this method has not yet been validated during ambulation or for individuals other
than young healthy males. To reduce the number of required measurement devices, researchers have
become increasingly creative in trying to eliminate the need for ECG and produce a more compact
design. For example, Huynh et al. [20] demonstrated that replacing ECG with IPG as a proximal timing
reference for PTT can enhance BP estimation, reporting an r of 0.88 for both SBP and DBP. The two
sensors were placed close to each other on the wrist and finger, indicating their potential application
in a convenient wearable device. The results are limited by a small sample size (n = 15) and lack of
hypertensive individuals.
Combining PPG with other biosignals for assessing comes with certain limitations, such as:
1. Synchronization between biosignals. If biosignals are not collected at the same time, PTT cannot be
determined accurately. Unfortunately, this point is overlooked and therefore, there is inconsistency
in reporting accuracy using PAT [86].
2. Calibration. Current PTT-BP estimations require calibration of PTT (ms) to BP (mmHg), which
is dependent on several patient-specific factors: distance between measurement sites, average
cross-sectional area of arteries between measurement sites, blood density, and the compliance
of arteries [87]. As the composition of arteries changes with age (elastin in central arteries
is replaced with collagen, which contributes to the atherosclerotic processes and stiffening of
arteries), these techniques require subject specific calibration using a BP cuff at intervals in-line
with atherosclerotic aging processes [87]. Mukkamala and Hahn [88] identified the maximum
calibration interval to be about one year at age 30 with a linear decline to roughly six months by
age 70. The need for calibration greatly limits the feasibility of these technologies, however new
techniques such as those from Kachuee et al. [59] have eliminated the need for calibration using a
machine learning approach. To avoid the calibration step (i.e., the step taken to map feature(s)
values to mmHg), risk stratification could be used as an alternative output. In other words,
build a model to classify PPG-based features into three classes: normotensive, pre-hypertensive,
and hypertensive, rather than proving a specific mmHg value [9,10,80,89].
3. Noise. Biosignals are easily affected by noise, which can change the wave morphologies. To reduce
noise in PPG signals, three main approaches were proposed in the literature: the use of filtering [90,91],
signal quality index [92], and machine learning [73].
These challenges that impact accuracy need to be addressed properly before running a study and
reporting findings.
4.2. Reporting of Patient Demographics
Our analysis of patient demographics showed that most published papers investigating the use
of PPG with other biosignals for BP estimation include a study population of healthy, normotensive
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individuals with no reported comorbidities. As BP monitoring devices will inherently be used more
often by people that have hypertension, researchers must be careful and thorough in collecting
data from this important population. Kim et al. [31] stated that the PTT-BP relationship in patients
with chronic heart failure is inconsistent and worsens with disease progression. This suggests that
the modified transmission of pulse waves in arteries experiencing disease-induced structural and
functional changes is a potential confounding factor. The finding of decreased PTT-BP accuracy in
patients with heart disease was also confirmed by Spiesshofer et al. [32] and Ding et al. [22].
4.3. Testing Conditions
In addition to reporting patient health status, we recommend that studies also report the
corresponding medications that participants are taking for their comorbidities. Given that a large
proportion of the population manages health conditions with medications, it is important to evaluate
the contribution that they have on the accuracy of PTT-based BP estimations. It has been shown that
vasoactive drugs significantly affect the calibration between PTT and mean arterial BP, and recalibration
is necessary to mitigate these changes and maintain measurement accuracy [41]. Additionally,
the administration of vasoactive drugs has been found to alter the vascular smooth muscle tone and,
in turn, the reliability of PTT for adequately predicting BP [35,71,84]. Therefore, it is imperative that
medications be reported and results be interpreted with this consideration in mind. Additionally,
PPT-BP measurements have been evaluated for use in patients undergoing general anesthesia [25,41]
as the induction of general anesthesia has been noted to be associated with considerable hemodynamic
instability in hypertensive patients. Kim et al. [31] investigated whether PTT-based BP measurements
were applicable in these conditions and concluded that such measurements could successfully track
the associated SBP changes.
4.4. Recommendations for Future Advancements
The current literature on BP measurement using multiple biosignals and PPG is promising.
Our key recommendations for future research endeavors are as follows:
− implementation of the IEEE guidelines for research regarding cuff-less BP devices, which
includes information pertaining to observer training and measurement, validation procedures
and appropriate gold standards, validation criteria, subject recruitment, and data reporting [93];
− inclusion of hypertensive and pregnant populations with improved reporting of gender and
health status;
− appropriate definition and application of PAT and PTT that account for PEP to improve the
measurement accuracy and decrease error;
− continued research on wearable devices that tests subjects during various ambulation activities,
especially research on noise- and calibration-reducing algorithms.
5. Conclusions
Hypertension is one of the most important risk factors for cardiovascular diseases and is the leading
cause of death worldwide. Thus, accurate BP monitoring is vital for effective management. Therefore,
the development of a noninvasive device for continuous BP measurement would afford significant
advantages to the medical community. However, research on hypertensive and pregnant individuals
is currently lacking and more research is needed to understand how these variations contribute to the
validity of results in these populations. Studies have tried to develop increasingly compact yet accurate
devices over recent years; however, current technologies face limitations in successfully incorporating
PPG and ECG into a single wearable device. Nonetheless, the successful validation of a publicly
available wearable device has the potential to increase awareness and self-management strategies for
the improved global prevention and management of cardiovascular disease.
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Abbreviations
Abbreviations of terms used in this review.
BP Blood pressure M1 Modality 1 (PPG + ECG)
PPG Photoplethysmography M2 Modality 2 (PPG + BCG)
PTT Pulse transit time M3 Modality 3 (PPG + SCG)
PAT Pulse arrival time M4 Modality 4 (PPG + IPG)
PWV Pulse wave velocity M5 Modality 5 (PPG + SBS)
PEP Pre-ejection period M6 Modality 6 (PPG + ICG)
AO Aortic opening M7 Modality 7 (PPG + ECG + ICG)
ECG Electrocardiography M8 Modality 8 (PPG + ECG + BCG)
ICG Impedance cardiography M9 Modality 9 (PPG + SCG + GCG)
BCG Ballistocardiography M10 Modality 10 (PPG + ECG + SCG)
SCG Seismocardiography ME Mean error
GCG Gyrocardiography SD Standard deviation
IPG Impedance plethysmography MIMIC Medical Information Mart for Intensive Care
SBS Strain based sensor AAMI
Association for the Advancement of
Medical Instrumentation
MAP Mean arterial pressure HTN Hypertension
SBP Systolic blood pressure NTN Normotension
DBP Diastolic blood pressure ABP Arterial invasive blood pressure
HR Heart rate CBP Cuff blood pressure
PIR PPG intensity ratio FABP Finger arterial blood pressure
HRPS Heart-power spectrum ration IEEE Institute of Electrical and Electronics Engineers
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